A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer
Status:
Withdrawn
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess whether a combination of chemotherapy,
Trastuzumab and RAD001 will result in no evidence of microscopic disease at the time of
surgery in 50% of enrolled patients.